bexicaserin (LP352) / Longboard Pharma  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
bexicaserin (LP352) / Longboard Pharma
NCT06149663: Intermediate-Size Expanded Access Protocol (EAP) for LP352

Available
N/A
US
LP352
Longboard Pharmaceuticals
Dravet Syndrome, Lennox Gastaut Syndrome, Developmental and Epileptic Encephalopathies
 
 

Download Options